Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward P Armstrong

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
Pharmacotherapy|March 26, 2004
Angiotensin-converting enzyme inhibitor therapy in patients with heart failure enrolled in a managed care organization: effect on costs and probability of hospitalizationJacob Abarca, Daniel C Malone, Edward P Armstrong, et al.
Journal of Managed Care Pharmacy : JMCP|November 14, 2003
Industry's perception of presenting pharmacoeconomic models to managed care organizationsBridget M Olson, Edward P Armstrong, Amy J Grizzle, et al.
American Journal of Alzheimer'S Disease and Other Dementias|December 1, 2012
Health disparities in cost of care in patients with Alzheimer's disease: an analysis across 4 state Medicaid populationsAdrienne M Gilligan, Daniel C Malone, Terri L Warholak, et al.
Stroke|November 15, 2012
Analysis of a coordinated stroke center and regional stroke network on access to acute therapy and clinical outcomesMarilyn M Rymer, Edward P Armstrong, Gary Walker, et al.
COPD|March 14, 2012
Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortalityPrasadini N Perera, Edward P Armstrong, Duane L Sherrill, et al.
Stroke|April 4, 2013
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillationAmanda R Harrington, Edward P Armstrong, Paul E Nolan, et al.
The American Journal of Geriatric Pharmacotherapy|October 16, 2012
Racial and ethnic disparities in Alzheimer's disease pharmacotherapy exposure: an analysis across four state Medicaid populationsAdrienne M Gilligan, Daniel C Malone, Terri L Warholak, et al.
Pharmacotherapy|June 5, 2007
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care SystemWei-Shi Yeh, Edward P Armstrong, Grant H Skrepnek, et al.
The Annals of Pharmacotherapy|April 20, 2006
Performance of drug-drug interaction software for personal digital assistantsNatalie A Perkins, John E Murphy, Daniel C Malone, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|September 5, 2008
Relationship between pharmaceutical services characteristics and exposure rates to drug-drug interactions in Veterans Affairs medical centersMaysaa H Mahmood, Edward P Armstrong, Daniel C Malone, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Pharmacotherapy|March 26, 2004
Angiotensin-converting enzyme inhibitor therapy in patients with heart failure enrolled in a managed care organization: effect on costs and probability of hospitalizationJacob Abarca, Daniel C Malone, Edward P Armstrong, et al.
Journal of Managed Care Pharmacy : JMCP|November 14, 2003
Industry's perception of presenting pharmacoeconomic models to managed care organizationsBridget M Olson, Edward P Armstrong, Amy J Grizzle, et al.
American Journal of Alzheimer'S Disease and Other Dementias|December 1, 2012
Health disparities in cost of care in patients with Alzheimer's disease: an analysis across 4 state Medicaid populationsAdrienne M Gilligan, Daniel C Malone, Terri L Warholak, et al.
Stroke|November 15, 2012
Analysis of a coordinated stroke center and regional stroke network on access to acute therapy and clinical outcomesMarilyn M Rymer, Edward P Armstrong, Gary Walker, et al.
COPD|March 14, 2012
Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortalityPrasadini N Perera, Edward P Armstrong, Duane L Sherrill, et al.
Stroke|April 4, 2013
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillationAmanda R Harrington, Edward P Armstrong, Paul E Nolan, et al.
The American Journal of Geriatric Pharmacotherapy|October 16, 2012
Racial and ethnic disparities in Alzheimer's disease pharmacotherapy exposure: an analysis across four state Medicaid populationsAdrienne M Gilligan, Daniel C Malone, Terri L Warholak, et al.
Pharmacotherapy|June 5, 2007
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care SystemWei-Shi Yeh, Edward P Armstrong, Grant H Skrepnek, et al.
The Annals of Pharmacotherapy|April 20, 2006
Performance of drug-drug interaction software for personal digital assistantsNatalie A Perkins, John E Murphy, Daniel C Malone, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|September 5, 2008
Relationship between pharmaceutical services characteristics and exposure rates to drug-drug interactions in Veterans Affairs medical centersMaysaa H Mahmood, Edward P Armstrong, Daniel C Malone, et al.
Pageof 8